$ADPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Adaptive Biotechnologies Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Adaptive Biotechnologies Corp. Get notifications about new insider transactions in Adaptive Biotechnologies Corp for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 2021 | ADPT | Adaptive Biotechno ... | GRIFFIN MICHELLE RENEE | Director | Option Exercise | M | 7.80 | 2,500 | 19,500 | 76,000 | |
| May 19 2021 | ADPT | Adaptive Biotechno ... | GRIFFIN MICHELLE RENEE | Director | Sell | S | 35.00 | 2,500 | 87,500 | 1,504 | 4 K to 1.5 K (-62.44 %) |
| May 19 2021 | ADPT | Adaptive Biotechno ... | GRIFFIN MICHELLE RENEE | Director | Buy | M | 7.80 | 2,500 | 19,500 | 4,004 | 1.5 K to 4 K (+166.22 %) |
| May 17 2021 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Option Exercise | M | 7.80 | 2,000 | 15,600 | 151,000 | |
| May 17 2021 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Sell | S | 33.80 | 2,000 | 67,600 | 20,604 | 22.6 K to 20.6 K (-8.85 %) |
| May 17 2021 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Buy | M | 7.80 | 2,000 | 15,600 | 22,604 | 20.6 K to 22.6 K (+9.71 %) |
| May 13 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.55 | 10,000 | 65,500 | 130,000 | |
| May 13 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.55 | 10,000 | 65,500 | 140,000 | |
| May 13 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 32.63 | 10,000 | 326,300 | 21,604 | 31.6 K to 21.6 K (-31.64 %) |
| May 13 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.55 | 10,000 | 65,500 | 31,604 | 21.6 K to 31.6 K (+46.29 %) |
| May 13 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 31.84 | 7,031 | 223,867 | 21,604 | 28.6 K to 21.6 K (-24.55 %) |
| May 13 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 30.81 | 2,969 | 91,475 | 28,635 | 31.6 K to 28.6 K (-9.39 %) |
| May 13 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.55 | 10,000 | 65,500 | 31,604 | 21.6 K to 31.6 K (+46.29 %) |
| May 07 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 3,895 | 24,616 | 128,535 | |
| May 07 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 3,895 | 24,616 | 132,430 | |
| May 07 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 36.38 | 847 | 30,814 | 69,360 | 70.2 K to 69.4 K (-1.21 %) |
| May 07 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 35.51 | 3,048 | 108,234 | 70,207 | 73.3 K to 70.2 K (-4.16 %) |
| May 07 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 3,895 | 24,616 | 73,255 | 69.4 K to 73.3 K (+5.62 %) |
| May 07 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 35.43 | 3,195 | 113,199 | 69,360 | 72.6 K to 69.4 K (-4.40 %) |
| May 07 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 3,895 | 24,616 | 73,255 | 69.4 K to 73.3 K (+5.62 %) |
| May 06 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 3,895 | 24,616 | 136,325 | |
| May 06 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 36.80 | 700 | 25,760 | 69,360 | 70.1 K to 69.4 K (-1.00 %) |
| May 06 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 35.99 | 3,195 | 114,988 | 70,060 | 73.3 K to 70.1 K (-4.36 %) |
| May 06 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 3,895 | 24,616 | 73,255 | 69.4 K to 73.3 K (+5.62 %) |
| May 03 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 31.71 | 1,354 | 42,935 | 46,042 | |
| May 03 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 6.55 | 1,770 | 11,594 | 19,480 | |
| May 03 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 7.80 | 1,042 | 8,128 | 25,000 | |
| May 03 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 41.93 | 4,166 | 174,680 | 15,036 | 19.2 K to 15 K (-21.70 %) |
| May 03 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 31.71 | 1,354 | 42,935 | 19,202 | 17.8 K to 19.2 K (+7.59 %) |
| May 03 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 6.55 | 1,770 | 11,594 | 17,848 | 16.1 K to 17.8 K (+11.01 %) |
| May 03 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 7.80 | 1,042 | 8,128 | 16,078 | 15 K to 16.1 K (+6.93 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 7,790 | 49,233 | 140,220 | |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 7,790 | 49,233 | 140,220 | |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 7,790 | 49,233 | 148,010 | |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 7,790 | 49,233 | 148,010 | |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,685 | 73,849 | 155,800 | |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,685 | 73,849 | 155,800 | |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 43.59 | 3,510 | 153,001 | 69,360 | 72.9 K to 69.4 K (-4.82 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 43.59 | 3,510 | 153,001 | 69,360 | 72.9 K to 69.4 K (-4.82 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 42.85 | 4,280 | 183,398 | 72,870 | 77.2 K to 72.9 K (-5.55 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 42.85 | 4,280 | 183,398 | 72,870 | 77.2 K to 72.9 K (-5.55 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 7,790 | 49,233 | 77,150 | 69.4 K to 77.2 K (+11.23 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 7,790 | 49,233 | 77,150 | 69.4 K to 77.2 K (+11.23 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 41.79 | 5,200 | 217,308 | 69,360 | 74.6 K to 69.4 K (-6.97 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 41.79 | 5,200 | 217,308 | 69,360 | 74.6 K to 69.4 K (-6.97 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 41.17 | 2,090 | 86,045 | 74,560 | 76.7 K to 74.6 K (-2.73 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 41.17 | 2,090 | 86,045 | 74,560 | 76.7 K to 74.6 K (-2.73 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 39.85 | 500 | 19,925 | 76,650 | 77.2 K to 76.7 K (-0.65 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 39.85 | 500 | 19,925 | 76,650 | 77.2 K to 76.7 K (-0.65 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 7,790 | 49,233 | 77,150 | 69.4 K to 77.2 K (+11.23 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 7,790 | 49,233 | 77,150 | 69.4 K to 77.2 K (+11.23 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 41.35 | 3,000 | 124,050 | 69,360 | 72.4 K to 69.4 K (-4.15 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 41.35 | 3,000 | 124,050 | 69,360 | 72.4 K to 69.4 K (-4.15 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 40.24 | 8,685 | 349,484 | 72,360 | 81 K to 72.4 K (-10.72 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 40.24 | 8,685 | 349,484 | 72,360 | 81 K to 72.4 K (-10.72 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,685 | 73,849 | 81,045 | 69.4 K to 81 K (+16.85 %) |
| Apr 22 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,685 | 73,849 | 81,045 | 69.4 K to 81 K (+16.85 %) |
| Apr 21 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, T ... | Option Exercise | M | 22.55 | 1,301 | 29,338 | 107,647 | |
| Apr 21 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, T ... | Sell | S | 41.25 | 1,301 | 53,666 | 9,158 | 10.5 K to 9.2 K (-12.44 %) |
| Apr 21 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, T ... | Buy | M | 22.55 | 1,301 | 29,338 | 10,459 | 9.2 K to 10.5 K (+14.21 %) |
| Apr 16 2021 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Option Exercise | M | 7.80 | 2,000 | 15,600 | 153,000 | |
| Apr 16 2021 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Sell | S | 43.04 | 2,000 | 86,080 | 20,604 | 22.6 K to 20.6 K (-8.85 %) |
| Apr 16 2021 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Buy | M | 7.80 | 2,000 | 15,600 | 22,604 | 20.6 K to 22.6 K (+9.71 %) |
| Apr 16 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Option Exercise | M | 7.80 | 2,000 | 15,600 | 339,250 | |
| Apr 16 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Sell | S | 44.50 | 2,000 | 89,000 | 22,894 | 24.9 K to 22.9 K (-8.03 %) |
| Apr 16 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Buy | M | 7.80 | 2,000 | 15,600 | 24,894 | 22.9 K to 24.9 K (+8.74 %) |
| Apr 16 2021 | ADPT | Adaptive Biotechno ... | GRIFFIN MICHELLE RENEE | Director | Option Exercise | M | 7.80 | 4,500 | 35,100 | 78,500 | |
| Apr 16 2021 | ADPT | Adaptive Biotechno ... | GRIFFIN MICHELLE RENEE | Director | Sell | S | 43.41 | 4,500 | 195,345 | 1,504 | 6 K to 1.5 K (-74.95 %) |
| Apr 16 2021 | ADPT | Adaptive Biotechno ... | GRIFFIN MICHELLE RENEE | Director | Buy | M | 7.80 | 4,500 | 35,100 | 6,004 | 1.5 K to 6 K (+299.20 %) |
| Apr 09 2021 | ADPT | Adaptive Biotechno ... | ADAMS R MARK | Chief Operating Off ... | Sell | S | 42.34 | 3,586 | 151,831 | 67,018 | 70.6 K to 67 K (-5.08 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 10,000 | 63,200 | 25,000 | |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 10,000 | 63,200 | 35,000 | |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 42.34 | 806 | 34,126 | 21,604 | 22.4 K to 21.6 K (-3.60 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 41.59 | 9,194 | 382,378 | 22,410 | 31.6 K to 22.4 K (-29.09 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 10,000 | 63,200 | 31,604 | 21.6 K to 31.6 K (+46.29 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.95 | 10,000 | 409,500 | 21,604 | 31.6 K to 21.6 K (-31.64 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 10,000 | 63,200 | 31,604 | 21.6 K to 31.6 K (+46.29 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 43.78 | 100 | 4,378 | 1,748,461 | 1.7 M to 1.7 M (-0.01 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 43.00 | 1,957 | 84,151 | 1,748,561 | 1.8 M to 1.7 M (-0.11 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 42.04 | 2,943 | 123,724 | 1,750,518 | 1.8 M to 1.8 M (-0.17 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 41.45 | 1,100 | 45,595 | 1,753,461 | 1.8 M to 1.8 M (-0.06 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 40.61 | 3,900 | 158,379 | 1,754,561 | 1.8 M to 1.8 M (-0.22 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 43.08 | 1,200 | 51,696 | 1,758,461 | 1.8 M to 1.8 M (-0.07 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 42.48 | 2,200 | 93,456 | 1,759,661 | 1.8 M to 1.8 M (-0.12 %) |
| Apr 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 41.08 | 1,600 | 65,728 | 1,761,861 | 1.8 M to 1.8 M (-0.09 %) |
| Apr 02 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 31.71 | 1,354 | 42,935 | 47,396 | |
| Apr 02 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 6.55 | 1,771 | 11,600 | 21,250 | |
| Apr 02 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 7.80 | 1,042 | 8,128 | 26,042 | |
| Apr 02 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 40.00 | 4,167 | 166,680 | 15,036 | 19.2 K to 15 K (-21.70 %) |
| Apr 02 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 31.71 | 1,354 | 42,935 | 19,203 | 17.8 K to 19.2 K (+7.59 %) |
| Apr 02 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 6.55 | 1,771 | 11,600 | 17,849 | 16.1 K to 17.8 K (+11.02 %) |
| Apr 02 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 7.80 | 1,042 | 8,128 | 16,078 | 15 K to 16.1 K (+6.93 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 5,290 | 33,433 | 167,485 | |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 6,395 | 40,416 | 172,775 | |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 7,790 | 49,233 | 179,170 | |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 38.72 | 1,481 | 57,344 | 69,360 | 70.8 K to 69.4 K (-2.09 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 38.13 | 3,809 | 145,237 | 70,841 | 74.7 K to 70.8 K (-5.10 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 5,290 | 33,433 | 74,650 | 69.4 K to 74.7 K (+7.63 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 41.76 | 400 | 16,704 | 69,360 | 69.8 K to 69.4 K (-0.57 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 40.33 | 4,175 | 168,378 | 69,760 | 73.9 K to 69.8 K (-5.65 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 39.43 | 1,820 | 71,763 | 73,935 | 75.8 K to 73.9 K (-2.40 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 6,395 | 40,416 | 75,755 | 69.4 K to 75.8 K (+9.22 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 41.93 | 7,790 | 326,635 | 69,360 | 77.2 K to 69.4 K (-10.10 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 7,790 | 49,233 | 77,150 | 69.4 K to 77.2 K (+11.23 %) |
| Mar 22 2021 | ADPT | Adaptive Biotechno ... | OWEN KATEY EINTERZ | Director | Option Exercise | A | 45.01 | 11,109 | 500,016 | 11,109 | |
| Mar 22 2021 | ADPT | Adaptive Biotechno ... | OWEN KATEY EINTERZ | Director | Grant | A | 0.00 | 4,443 | 0 | 4,443 | 0 to 4.4 K |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Option Exercise | M | 22.55 | 16,052 | 361,973 | 108,948 | |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Sell | S | 45.32 | 1,739 | 78,811 | 9,158 | 10.9 K to 9.2 K (-15.96 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Sell | S | 43.83 | 5,971 | 261,709 | 10,897 | 16.9 K to 10.9 K (-35.40 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Sell | S | 43.04 | 8,342 | 359,040 | 16,868 | 25.2 K to 16.9 K (-33.09 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Buy | M | 22.55 | 16,052 | 361,973 | 25,210 | 9.2 K to 25.2 K (+175.28 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 42.48 | 100 | 4,248 | 1,763,461 | 1.8 M to 1.8 M (-0.01 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 41.96 | 4,900 | 205,604 | 1,763,561 | 1.8 M to 1.8 M (-0.28 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 43.78 | 470 | 20,577 | 1,768,461 | 1.8 M to 1.8 M (-0.03 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 42.81 | 2,604 | 111,477 | 1,768,931 | 1.8 M to 1.8 M (-0.15 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 41.90 | 1,926 | 80,699 | 1,771,535 | 1.8 M to 1.8 M (-0.11 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 45.25 | 1,804 | 81,631 | 1,773,461 | 1.8 M to 1.8 M (-0.10 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 44.03 | 1,295 | 57,019 | 1,775,265 | 1.8 M to 1.8 M (-0.07 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 43.22 | 1,901 | 82,161 | 1,776,560 | 1.8 M to 1.8 M (-0.11 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Trigg Leslie | Director | Option Exercise | A | 45.01 | 11,109 | 500,016 | 11,109 | |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Trigg Leslie | Director | Grant | A | 0.00 | 4,443 | 0 | 4,443 | 0 to 4.4 K |
| Mar 12 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 10,000 | 63,200 | 45,000 | |
| Mar 12 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 42.54 | 10,000 | 425,400 | 21,604 | 31.6 K to 21.6 K (-31.64 %) |
| Mar 12 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 10,000 | 63,200 | 31,604 | 21.6 K to 31.6 K (+46.29 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 42.38 | 30,268 | 1,282,664 | 12,309,090 | 12.3 M to 12.3 M (-0.25 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 41.47 | 25,732 | 1,067,037 | 12,339,358 | 12.4 M to 12.3 M (-0.21 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 41.16 | 34,302 | 1,411,887 | 12,365,090 | 12.4 M to 12.4 M (-0.28 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 40.42 | 215,698 | 8,719,333 | 12,399,392 | 12.6 M to 12.4 M (-1.71 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 41.62 | 85,911 | 3,575,753 | 12,615,090 | 12.7 M to 12.6 M (-0.68 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 41.21 | 71,194 | 2,933,641 | 12,701,001 | 12.8 M to 12.7 M (-0.56 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 39.97 | 33,600 | 1,343,039 | 12,772,195 | 12.8 M to 12.8 M (-0.26 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 39.22 | 75,000 | 2,941,163 | 12,805,795 | 12.9 M to 12.8 M (-0.58 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 38.22 | 234,295 | 8,954,310 | 12,880,795 | 13.1 M to 12.9 M (-1.79 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 10,000 | 63,200 | 55,000 | |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.79 | 2,890 | 117,883 | 21,064 | 24 K to 21.1 K (-12.06 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.02 | 7,110 | 284,542 | 23,954 | 31.1 K to 24 K (-22.89 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 10,000 | 63,200 | 31,064 | 21.1 K to 31.1 K (+47.47 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Option Exercise | M | 0.45 | 2,000 | 900 | 53,000 | |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 44.56 | 2,000 | 89,120 | 0 | 2 K to 0 (-100.00 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Buy | M | 0.45 | 2,000 | 900 | 2,000 | 0 to 2 K |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Option Exercise | M | 0.45 | 2,000 | 900 | 53,000 | |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 44.56 | 2,000 | 89,120 | 1,504 | 3.5 K to 1.5 K (-57.08 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Buy | M | 0.45 | 2,000 | 900 | 3,504 | 1.5 K to 3.5 K (+132.98 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Option Exercise | A | 43.68 | 57,234 | 2,499,981 | 57,234 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Grant | A | 0.00 | 22,894 | 0 | 22,894 | 0 to 22.9 K |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | A | 43.68 | 114,469 | 5,000,006 | 114,469 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Grant | A | 0.00 | 45,788 | 0 | 45,788 | 0 to 45.8 K |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | A | 43.68 | 171,703 | 7,499,987 | 171,703 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Grant | A | 0.00 | 68,681 | 0 | 69,360 | 679 to 69.4 K (+10,115.02 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | A | 43.68 | 34,341 | 1,500,015 | 34,341 |